Inactive Instrument

Orchid Pharma Limited Share Price Bombay S.E.

Equities

524372

INE191A01019

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 8.19B 98.09M 7.73B Sales 2025 * 10.28B 123M 9.71B Capitalization 53.65B 642M 50.64B
Net income 2024 922M 11.04M 870M Net income 2025 * 1.49B 17.79M 1.4B EV / Sales 2024 6.31 x
Net cash position 2024 1.32B 15.81M 1.25B Net cash position 2025 * 1.65B 19.73M 1.56B EV / Sales 2025 * 5.06 x
P/E ratio 2024
72.1 x
P/E ratio 2025 *
35.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 26.03%
More Fundamentals * Assessed data
Dynamic Chart
Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam MT
Orchid Pharma Receives DCGI Approval for Its First Invented and Made-In-India Antibiotic Drug Combination of Cefepime and Enmetazobactam CI
Transcript : Orchid Pharma Limited, Q4 2024 Earnings Call, May 24, 2024
Orchid Pharma Limited Appoints Shubha Singh as Additional Director CI
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Orchid Pharma Limited Receives Order from Office of Assistant Commissioner Valluvarkottam Central-III Chennai Central CI
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 30/03/20
Director of Finance/CFO - 28/06/20
Compliance Officer - 12-15
Members of the board TitleAgeSince
Chairman 74 30/03/20
Director/Board Member 42 30/03/20
Chief Executive Officer 56 30/03/20
More insiders
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW